CAH
CARDINAL HEALTH INC.
(NYSE:CAH)
Balfour Capital Group has issued a buy recommendation
for Cardinal Health Inc. (CAH) on July 30th, 2023.
Cardinal Health, Inc., headquartered in Dublin, Ohio, is an American multinational health care services company. It distributes pharmaceuticals and medical products to over 100,000 locations and supplies over 75% of U.S. hospitals, also manufacturing gloves, surgical apparel, and fluid management products.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $92.19 on July 30th, 2023.
- Our designated price target stands at $155.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q3 EARNING REPORT
A Q3 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Cardinal Health Inc. (CAH)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
HAL
HALLIBURTON CO
(NYSE:HAL)
Balfour Capital Group has issued a buy recommendation
for Halliburton Co (HAL) on July 30th, 2023.
Halliburton Company, headquartered in Houston and Dubai, is an American multinational oil service corporation, employing around 55,000 people across 70 countries. Specializing in fracking, its major segment is the Energy Services Group. Halliburton has faced controversies, including legal issues related to bribery, the Iraq War, and environmental transparency.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $38.57 on July 30, 2023.
- Our designated price target stands at $60.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy HALLIBURTON CO (HAL)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
PSX
PHILLIPS 66
(NYSE:PSX)
Balfour Capital Group Researched Phillips 66Â on August 10th, 2023.
Phillips 66 is a diversified energy manufacturing and logistics company headquartered in Houston, Texas. Established in 2012 following its spinoff from ConocoPhillips, the company operates across various segments, including refining, midstream, chemicals, and marketing specialties. Phillips 66 is involved in refining crude oil, transporting and marketing natural gas liquids (NGLs) and petrochemicals, and is active in the research and development of emerging energy sources. The company also has a joint venture with Chevron, known as Chevron Phillips Chemical.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $115.52 on August 10th, 2023.
- Our designated price target stands at $135.00.
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy PHILLIPS 66 (PSX) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
NVDA
NVIDIA CORP
(NASDAQ:NVDA)
Balfour Capital Group Researched Nvidia Corp on August 24th, 2023.
NVIDIA Corporation, a technology leader, revolutionizes industries with GPUs and AI solutions. Renowned for innovation, it empowers gaming, AI research, and high-performance computing.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $47.11 on August 24th, 2023.
- Our designated price target stands at $100.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy NVIDIA CORP (NASDAQ:NVDA) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
DIS
WALT DISNEY CO
(NYSE:DIS)
Balfour Capital Group Researched the Walt Disney Company On August 30th, 2023.
The Walt Disney Company, founded in 1923, is a global entertainment giant known for its iconic characters, theme parks, films, and media networks, impacting diverse industries worldwide.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $84.40 on August 30th, 2023.
- Our designated price target stands at $150.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Walt Disney Co (NYSE:DIS)​ is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
MMM
3M COMPANY
(NYSE: MMM)
Balfour Capital Group Researched 3M Company on August 30th, 2023.
3M Company, originally known as Minnesota Mining and Manufacturing Company, is a diversified technology and manufacturing firm. The company operates in various sectors, including industrial, safety, consumer products, healthcare, and electronics. Its product portfolio encompasses items such as adhesives, abrasives, laminates, passive fire protection, personal protective equipment, dental and orthodontic products, electronic materials, medical products, car-care products, and optical films.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $89.42 on August 30th, 2023.
- Our designated price target stands at $135.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy 3M COMPANY
(MMM) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
AMGN
AMGEN INC.
(NASDAQ:AMGN)
Balfour Capital Group has issued a buy recommendation for Amgen Inc. (AMGN) on September 5th, 2023.
Amgen Inc., established in 1980, is a leading biotechnology company dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas such as oncology, inflammation, general medicine, and rare diseases, aiming to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $256.71 on September 5th, 2023.
- Our designated price target stands at $350.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Amgen Inc. (AMGN)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
TMO
THERMO FISHER SCIENTIFIC INC
(NYSE:TMO)​
Balfour Capital Group Researched Thermo Fisher Scientific Inc on September 5th, 2023.
Thermo Fisher Scientific Inc. is a global leader in serving science, with annual revenue exceeding $40 billion. The company’s mission is to enable customers to make the world healthier, cleaner, and safer. They support customers in accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, and increasing laboratory productivity. Their extensive product portfolio includes laboratory supplies, equipment, instruments, clinical and diagnostics tools, and services for pharmaceutical and biotechnology companies.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $542.01 on September 5th, 2023.​
- Our designated price target stands at $710.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy THERMO FISHER SCIENTIFIC INC (TMO)​ is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
MCK
MCKESSON CORPORATION
(NYSE:MCK)
Balfour Capital Group Researched McKesson Corporation on September 11th, 2023.
McKesson Corporation is a leading healthcare services and information technology company operating in the United States and internationally. The company collaborates with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services that make quality care more accessible and affordable.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $420.78 on September 11th, 2022.​
- Our designated price target stands at $649.29
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy MCKESSON CORPORATION (MCK) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
FSLR
FIRST SOLAR INC
(NASDAQ:FSLR)
Balfour Capital Group Researched First Solar Inc (FSLR) on September 25th, 2023.
Founded in 1999, First Solar is a leading American solar technology company specializing in the design and manufacture of advanced thin-film photovoltaic (PV) solar modules. The company provides eco-efficient solar modules and is unique among the world’s largest solar manufacturers for being the only U.S.-headquartered company not manufacturing in China. First Solar’s advanced thin-film PV modules offer a high-performance, lowercarbon alternative to conventional crystalline silicon panels.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $164.00 on September 25th, 2023.
- Our designated price target stands at $250.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy FIRST SOLAR INC (FSLR)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
